Tagged Articles

AndroGel 179 articles

Plaintiff awarded $3.2M in AndroGel side effects retrial

An Illinois federal jury awarded an Oregon man $3.2 million, finding drug maker AbbVie Inc., was negligent in its promotion of the testosterone replacement therapy AndroGel. The verdict in the case of plaintiff Jesse Mitchell came after a more than two-week-long trial and resulted in an award of $200,000 in compensatory damages and $3 million in punitive damages. It was the second time a jury deliberated on whether AndroGel caused Mitchell’s heart attack. The first trial ended last summer with a jury finding AndroGel was not the cause of Mitchell’s heart attack and thus no compensatory damages were awarded. But the ... Read More

AbbVie faces fourth testosterone side effects trial

AbbVie Inc. will continue to use deceptive practices to market its testosterone replacement therapy AndroGel unless it is sent a firm message and faces financial pressure, say attorneys for a man who blames his heart attack on the drug. The jury in the fourth bellwether trial against AbbVie in a multidistrict litigation heard testimony alleging testosterone manufacturers did not adequately warn of cardiovascular risks with their testosterone treatments. Jesse Mitchell’s case was the first to go to trial and accuse AbbVie of failing to warn that AndroGel could increase the risk of heart attacks, strokes and blood clots, some of ... Read More

New trial begins in first testosterone side effects bellwether

A new trial began last week in the case of a man who won a $150 million verdict against Abbvie Inc., after arguing that the company’s testosterone replacement therapy AndroGel caused his heart attack. Plaintiff Jesse Mitchell claims he didn’t know that using the topical testosterone replacement therapy could put him at risk for heart attacks, strokes and blood clots because AbbVie failed to adequately warn consumers or health care professionals. His was the first case to go to trial among thousands in a multidistrict litigation naming several testosterone treatment makers. The first trial ended with a jury award of ... Read More

Judge orders new trial in first testosterone side effects bellwether

U.S. District Judge Matthew Kennelly ordered a new trial in the first bellwether against AbbVie Inc., in a multidistrict litigation accusing testosterone replacement therapy manufacturers of failing to warn of cardiovascular risks, finding that the jury must have misunderstood the issue of causation. Plaintiff Jesse Mitchell claimed AbbVie’s testosterone treatment AndroGel was not adequately tested to better understand its cardiovascular risks. Despite this, the company aggressively marketed the drug for the off-label treatment of a made-up condition they called Low T. The jury awarded Mitchell $150 million in punitive damages, finding the company misrepresented its testosterone therapy. But the jury ... Read More

Three drug makers reach tentative settlement in testosterone side effects MDL

Three manufacturers of testosterone replacement therapies among several in a multidistrict litigation accusing the companies of failing to warn consumers about cardiovascular risks with their products, have notified an Illinois federal judge that they have reached a tentative deal to settle the cases in which they are named. U.S. District Judge Matthew Kennelly told the manufacturers – Endo Pharmaceuticals Inc., Auxilium Pharmaceuticals LLC and GlaxoSmithKline LLC – that he would place a 45-day stay on the cases against them while the details of the settlement are worked out. He also told the remaining defendants – including AbbVie Inc., and Actavis ... Read More

Patient asks that new AndroGel side effects trial be on all claims

Jesse Mitchell asked an Illinois federal court to order a new trial on all his claims against testosterone manufacturer AbbVie Inc., instead of just one claim in the first bellwether in a multidistrict litigation accusing makers of testosterone replacement therapies of misrepresenting their products and failing to warn that their treatments were linked to cardiovascular risks. Jurors in that case did not find Abbie’s AndroGel as the cause of Mitchell’s heart attack, but did find the company guilty of fraudulently misrepresenting the testosterone treatment through alleged off-label marketing. As a result, they awarded Mitchell no compensatory damages, but did award ... Read More

Testosterone lawsuits blame makers for failing to warn of drug’s risks

AbbVie won the latest testosterone side effects lawsuit alleging its testosterone replacement therapy AndroGel caused a man to suffer debilitating blood clots, but the two previous plaintiffs wins with verdicts totaling nearly $300 million suggest the fight has only just begun. AbbVie’s AndroGel has enjoyed the lion’s share of sales in the once-booming testosterone replacement therapy market. The hormone treatment was approved by the Food and Drug Administration (FDA) in 2000 for the treatment of hypogonadism, a condition in which there is a testosterone deficiency due to a genetic defect, illness or trauma. But AbbVie began aggressively promoting the drug ... Read More

AndroGel asks for new trial after $140M verdict

AbbVie Inc., asked an Illinois federal judge for a new trial in a case involving claims the company failed to warn that its testosterone replacement therapy AndroGel could cause cardiovascular risks. AbbVie was slapped with $140 million in damages after a jury found the company liable for plaintiff Jeffrey Konrad’s 2010 heart attack. AbbVie argued that the plaintiff’s claims that the company was negligent and misrepresentative required Konrad to prove causation and unreasonable dangerousness. “By finding for AbbVie on one claim and for the plaintiff on the other, the jury necessarily reached inconsistent conclusions on one or both of those ... Read More

Yale doc says AndroGel caused blood clots in man’s lungs

A Yale School of Medicine physician, testifying on behalf of a man who blamed AbbVie Inc.’s AndroGel for causing blood clots in his lungs, said that the hormone replacement therapy does, in fact, increase the risk of dangerous blood clots in men who use the treatment. Yale hematologist Dr. Henry Rinder told an Illinois federal jury earlier this week that he believes that plaintiff Robert Nolte would not have suffered from a pulmonary embolism – or blood clots in his lungs – and several related injuries had he not been taking AndroGel. Nolte is suing AbbVie for failing to warn ... Read More

Lilly pulls Axiron from Korean market

Eli Lilly & Co. has taken its topical testosterone replacement therapy Axiron off the market in Korea after gaining the blessing of the country’s Ministry of Food and Drug Safety. The company said that it made the decision to withdraw the treatment from the market in Korea due to several factors including “low male menopause awareness and the existence of substitutable medicines.” Axiron was developed by Australian pharmaceutical company Acrux and marketed by U.S.-based Lilly. It was approved by the U.S. Food and Drug Administration (FDA) in 2010 for the treatment of hypogonadism, a condition in which men do not ... Read More